Tracers / [188Re]Re-188-HYNIC-BBN
[188Re]Re-188-HYNIC-BBN
Also written as Re-188-HYNIC-BBN; Re-188-HYNICBBN
- Radionuclide
- Re-188 t½ 1020 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- HYNIC-conjugated bombesin peptide analogue
- Target / mechanism
- Gastrin-releasing peptide receptor (GRPR) PMID 39036461
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | > 95% | HYNIC-BBN | 39036461 2024 Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [188Re]Re-188-HYNIC-BBN, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39036461: 'HYNIC-BBN'.